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Background: Neovascularization, a critical component of plaque vulnerability, appears to be mediated by vascular endothelial growth factor 
(VEGF). We aimed to reduce neovascularization and intimal hyperplasia in hypercholesterolemic rabbits, using local delivery of bevacizumab, an 
antibody specific for VEGF
Methods: Ten New Zealand white rabbits were fed with atherogenic diet for 3 weeks. Eleven biodegradable bevacizumab-eluting stents (BES) were 
implanted in the distal aorta. The control group consisted of 7 New Zealand white rabbits treated with 7 bare metal stents covered by biodegradable 
polymer. All animals were treated with aspirin and clopidogrel for 4 weeks. Follow-up angiography and Optical Coherence Tomography (OCT) study 
were scheduled at 4 weeks. OCT images of each stent were analyzed and each strut was examined for apposition. A strut was defined as embedded 
when it was buried in the intima for more than half of its thickness, protruding when apposed to the intima but not embedded, and malapposed 
when there was no intimal contact. Tissues were obtained for immunohistological analysis
Results: Angiography and OCT in all stented arteries revealed no stent thrombosis or restenosis. We acquired 121 cross-sectional images from 110 
mm in the stents of the BES group and 77 cross-sectional images from 70 mm in the stents in the control group. From the total of 1103 struts in 
the BES group, 1075 (97.5%) were embedded, while 28 (2.5%) struts were protruding and none malapposed. In the control group, 710 struts were 
analyzed, of which 697 were embedded (98.1%), 13 protruding (1.9%), and none malapposed (p=NS). Mean neointimal area in the BES group was 
0.15±0.09 mm2 comprising 2.45% of the lumen area, versus 0.78±0.21 mm2 and 14.3% respectively in the control group (p <0.001). Maximal 
intimal thickness was significantly lower in the BES group compared to the control (60±11 um versus 135±7 um, p<0.001). BES treated arterial 
segments had significantly decreased microvessel density compared to the control group (1.7±0.7 vessels per mm2 vs 15.5±1.2 vessels per mm2, 
p<0.001)
Conclusions: This study demonstrated the safety and effectiveness of a dedicated biodegradable drug eluting stent in an animal model
